LTFS
IHE icon

Ladenburg Thalmann Financial Services’s iShares US Pharmaceuticals ETF IHE Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio IHE Stock Details IHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$569K Sell
10,647
-2,826
-21% -$139K ﹤0.01% 1706
2019
Q3 		$629K Buy
13,473
+1,317
+11% +$63.1K ﹤0.01% 1577
2019
Q2 		$611K Sell
12,156
-330
-3% -$16.3K ﹤0.01% 1587
2019
Q1 		$641K Sell
12,486
-5,205
-29% -$259K ﹤0.01% 1493
2018
Q4 		$830K Sell
17,691
-8,742
-33% -$448K 0.01% 1167
2018
Q3 		$1.48M Buy
26,433
+14,760
+126% +$807K 0.01% 882
2018
Q2 		$574K Hold
11,673
– – 0.01% 1465
2018
Q1 		$574K Sell
11,673
-939
-7% -$48.2K 0.01% 1465
2017
Q4 		$649K Buy
12,612
+1,095
+10% +$56.3K 0.01% 1354
2017
Q3 		$599K Buy
11,517
+804
+8% +$41.3K 0.01% 1334
2017
Q2 		$552K Sell
10,713
-279
-3% -$14.1K 0.01% 1324
2017
Q1 		$548K Sell
10,992
-684
-6% -$33.9K 0.01% 1276
2016
Q4 		$549K Buy
11,676
+318
+3% +$15.1K 0.01% 1200
2016
Q3 		$566K Sell
11,358
-5,517
-33% -$280K 0.01% 1118
2016
Q2 		$813K Sell
16,875
-609
-3% -$29K 0.01% 852
2016
Q1 		$798K Buy
17,484
+4,545
+35% +$213K 0.01% 797
2015
Q4 		$697K Sell
12,939
-48,378
-79% -$2.55M 0.01% 848
2015
Q3 		$3.03M Sell
61,317
-6,609
-10% -$379K 0.06% 290
2015
Q2 		$3.96M Buy
67,926
+32,100
+90% +$1.88M 0.07% 263
2015
Q1 		$2.06M Buy
35,826
+20,754
+138% +$1.14M 0.04% 416
2014
Q4 		$761K Buy
15,072
+7,881
+110% +$384K 0.02% 712
2014
Q3 		$336K Sell
7,191
-1,416
-16% -$63.9K 0.01% 969
2014
Q2 		$388K Buy
8,607
+651
+8% +$28K 0.01% 877
2014
Q1 		$336K Buy
7,956
+2,622
+49% +$110K 0.01% 886
2013
Q4 		$210K Buy
5,334
+741
+16% +$27.8K 0.01% 1053
2013
Q3 		$163K Buy
4,593
+747
+19% +$26.3K 0.01% 1103
2013
Q2 		$128K Buy
+3,846
New +$128K ﹤0.01% 1185

Other funds holding IHE

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MCM
Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Ladenburg Thalmann Financial Services's IHE Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services reduced its iShares US Pharmaceuticals ETF (IHE) stake by 21% in Q4 2019, selling an estimated $139K and leaving 10,647 shares worth $569K. The position accounts for ﹤0.01% of the portfolio, ranked #1706.

Ladenburg Thalmann Financial Services first reported a position in IHE in Q2 2013 and has held it in 27 quarters since. The position peaked at $3.96M in Q2 2015. 95 funds tracked by Wall St. Rank hold IHE as of Q4 2019.

  • Ladenburg Thalmann Financial Services held 10,647 shares of iShares US Pharmaceuticals ETF worth $569K as of Q4 2019.
  • Ladenburg Thalmann Financial Services sold 2,826 iShares US Pharmaceuticals ETF shares in Q4 2019, an estimated $139K.
  • iShares US Pharmaceuticals ETF made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #1706 holding.
  • Ladenburg Thalmann Financial Services first reported a position in iShares US Pharmaceuticals ETF in Q2 2013 and has held it in 27 quarters since.
  • Ladenburg Thalmann Financial Services's iShares US Pharmaceuticals ETF position peaked at $3.96M in Q2 2015.
  • 95 funds tracked by Wall St. Rank held iShares US Pharmaceuticals ETF as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.